ARS Pharmaceuticals Faces Lawsuit Over CVS Caremark Formulary Deadline

ARS Pharmaceuticals Inc. faces a securities class action lawsuit stemming from its communications about the timeline for gaining inclusion on CVS Caremark's drug formulary. The lawsuit alleges that ARS Pharmaceuticals built analyst expectations around a July 1, 2026, coverage timeline without disclosing that this date was at risk of slipping to January 2027.

The legal action includes a reminder to shareholders that the lead plaintiff deadline is October 5, 2026. The situation intensified after the missed CVS Caremark formulary date was described as a "negative shock" in the market.

According to the complaint, ARS Pharmaceuticals failed to adequately disclose the risk that the company's product might not meet the January 2027 target for inclusion on the CVS Caremark formulary. This alleged lack of transparency impacted investor expectations significantly.

Further details of the lawsuit and its potential ramifications for the company are emerging. Shareholders are advised to consult the legal filings and contact counsel regarding their rights.